Dr. Falk CEC-3/CEL

Full title: A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet

Details: This is a double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of three different doses (0.5, 1 and 2 mg TID) of Larazotide Acetate as an adjunct to gluten-free diet in the treatment of patients with celiac disease (CD)

Specialty: Gastroenterology

Principal Investigator: Dr Valerie Byrnes

Study status: Follow up

Identifier: NCT01396213